Klaus Ort’s Post

Recent success stories in the German biotech industry are setting an end to the muted M&A market, underscoring its innovation power and international attractiveness. Stay tuned for the upcoming EY German Biotech Report 2024, providing key insights on this industry!

Last year was pretty bleak across the CDMO space; most companies did well to tread water and many had to go one step further and scale back on operations; focusing on a core offering and keeping their powder dry for sunnier days ahead. Understandable considering that 2023 was dominated by high interest rates and a lot of course-correction after some overly optimistic covid-investments... 👀 Over halfway through 2024 and the signs are more positive. 📈 - FUJIFILM Diosynth Biotechnologies investment of $1.2bn in NC over the next 7y - Corden Pharma - A Full-Service CDMO investing $0.5bn in CO - Acquisitions are back, Novo Nordisk grabbing the headlines with their move on Catalent Pharma Solutions in February but also Bora Pharmaceuticals acquiring Emergent BioSolutions CDMO capability in Baltimore and Lonza taking over Roche/Genentech's Vacaville biologics site Of course, there are plenty of examples that are less-encouraging but overall the direction of travel seems to be onwards and upwards - in line with Alvarez & Marsal's CDMO projections for 2030 (see my previous post - https://shorturl.at/qfIxg). #Biotech #CDMO #Investment Sources: https://shorturl.at/EOfVk https://shorturl.at/hz9O3 https://shorturl.at/wpaiN

How has Swiss biotech been performing in 2023? 📈 In April the Swiss Biotech Report 2024 was released and its findings were very encouraging for Switzerland's biotech landscape. 2023 marked a 50% increase in capital investment compared to 2022 and reached $2.2 billion. The industry also achieved a revenue of $8 billion in Switzerland. 💸 With public and private companies raising significant funds and Swiss contributions to the cautious yet optimistic IPO market, the country remains a leader in the industry. 🏅 Find out more in the article! ⬇️ https://lnkd.in/devcxekD #swissbiotech #SwissBiotechReport #capitalinvestment #revenuegrowth #IPO #biotechindustry #innovation #healthcare #Switzerland #biotechnews #pharma NewBiologix | Noema Pharma | Alentis Therapeutics | Rejuveron Life Sciences AG | MoonLake Immunotherapeutics (NASDAQ: MLTX) | Lonza | Oculis | CRISPR Therapeutics | Vertex Pharmaceuticals | Novartis | Roche | Flatiron Health | University of Pennsylvania

🌾 𝗪𝗵𝗲𝗮𝘁'𝘀 𝗪𝗲𝗲𝗸𝗹𝘆!! 🌾 What a week it's been, obviously the huge news about Novo Holdings acquiring Catalent Pharma Solutions, but there is plenty more thats happened this week in the CDMO space - #wheatsweekly   𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗡𝗲𝘄𝘀! 🤜 Fozia Saleem, CEO of Magnitude Biosciences, has been named on the Northern Power Women Awards’ ‘Future List’—a list of powerful and influential women who are acknowledged as change makers and leaders in their field. 🤜 AbbVie immunology portfolio revenues were down 12% in Q4 to $6.95 billion, due to Humira biosimilar competition. Global Humira sales were $3.3 billion, down 41%.   💊 🧬    𝗠&𝗔 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗲𝗲𝗸! 🤜 3P Biopharmaceuticals and Biovian have merged together to form 3PBIOVIAN, a brand new pure play European CDMO with the funding of their common shareholder Keensight Capital. 🤜 Novo Nordisk acquire 3 of Catalent Pharma Solutions fill/finish sites after the acquisition from their investment company Novo Holdings.   🤝💼    𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗲𝗲𝗸! 🤜 Sai Life Sciences Ltd has expanded its DMPK capabilities with the addition of 25,000 sq. ft. of labs equipped with cutting-edge instrumentation enabling high-end automation. 🤜 Resilience and Taiwan Manufacturing Corporation, have announced a joint venture which aims to transform the biomanufacturing industry, addressing the growing need for technology enabled, end-to-end solutions for complex medicines.    🏭🌎    𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗲𝗲𝗸! 🤜 AbbVie strengthened its manufacturing capabilities by breaking ground on a new $223 million expansion of its Singapore manufacturing facility which will ass 100 jobs and new biologics manufacturing capacity.   🤑💰    𝗡𝗲𝘄 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽! 🤜 Matica Biotechnology, Inc. have named Paul Kim as CEO, he brings 3 decades of experience working for similar CDMO's and led the first global biotech fund focusing on innovative Asian biotech investments. 🤜 Scorpius BioManufacturing, Inc. has promoted Joseph Payne to COO who has over 20 years experience and has participated in 40+ regulatory inspections and has extensive knowledge of global regulatory agency requirements. 👨🔬👩🔬    Did I miss anything, let me know in the comments! 👇    #pharma #biotech #cdmo #lifescience   

Bridging the gap between innovation and later-stage financing for biotech in Europe Jing Gong, Jean-Loup Romet-Lemonne, & Brandy Houser, https://lnkd.in/dfd-3aBA. Highlights: 1) In 2021-22, US biotechs received $15.5 billion in later-stage financing, while European biotech received only $2.1bn (Fig 1a) 2) At series A, the median deal value for a European biotech is two-thirds that of a US biotech, with less than half the number of deals occurring (Fig. 1b). This deviation becomes more evident at series B and series C as the number of deals for European biotechs diminishes further and the gap between the median deal value in Europe and the USA widens 3) Over 2022, median deal size for series B-F in the USA was around $260 million, compared to only $100m in Europe (Fig 1c) Further resources: 1) Burning bright https://lnkd.in/dCsjAA_t 2) Venture capital in biotech from 2018 to 2023 https://lnkd.in/gaKCwDBR 3) How good an investment is the biopharmaceutical industry https://lnkd.in/dBS9zTpA 4) Early stage biotech investing https://lnkd.in/dbgwcDiW 5) Early stage returns https://lnkd.in/dCmfR9wj

#BIOEurope is Europe's premier partnering event for the life sciences industry, bringing together thousands of executives from biotechnology, pharmaceutical, and finance companies. This event offers an unmatched opportunity to network, forge partnerships, and discover the latest innovations in #biotech. A key highlight of this year’s conference is Merck Group’s EMEA Advance Biotech Grant Program, designed to help emerging biotech companies accelerate their journey to commercialization! Is your company developing breakthrough biologics or pioneering new therapies? Then, this is a valuable platform to kickstart your next big step in innovation. Five selected companies will have the chance to showcase their work to industry leaders and Merck’s Grant representatives, gaining invaluable visibility and support. The program offers access to advanced bioprocessing technologies and expert consultation from M Ventures —resources that can elevate your biotech advancement. 📅 With the application deadline on September 9, 2024, now is the time to step up and secure your spot among industry frontrunners. Don’t miss this chance—apply now and make your mark at BIO-Europe! https://lnkd.in/dxVe5ctU 🔬💡 #Innovation #Healthcare #Biotechnology #Merck

good article in todays The Australian Financial Review on #asx #biotech sector. Hugh Dive CFA the chief investment officer at Atlas Funds Management says picking biotech winners is tricky because each company is underpinned by inherently complex science and “So much rests on understanding the science, so you get a very binary outcome – either it works fabulously, or it goes to zero,” Some recent very good performers include Telix Pharmaceuticals Limited Clarity Pharmaceuticals. Recce Pharmaceuticals Ltd is also reporting excellent data from #clinicaltrials and looks set for a good run. congratulations BLINKLAB - Neurobehavioral Testing and Anton Uvarov PhD MBA on great #IPO. Here in Germany, European investors continue to look for quality ASX biotech stocks with a dual-listing in Germany. #biotechinvesting #pharma #impactinvesting #capitalmarkets #bourse #investorrelations

📰 Hungarian pharmaceutical company Richter Gedeon Nyrt. / Magyarország announced the acquisition of a 9.08% stake in German biosimilar maker Formycon AG. The companies said in a press release that they intend to combine their complementary strengths for the development of biologic therapies, with Formycon's clear focus as a leading and independent developer of biosimilars and Gedeon Richter's reach as a large multinational company with core competencies in research and manufacturing. Richter noted that global sales of biosimilars could rise from more than $15 bln at present to over $74 bln by 2030. Read further comments from Formycon’s CEO, Stefan Glombitza, Enno Spillner, CFO of Formycon and Gabor Orban, CEO of Gedeon Richter 👉 https://lnkd.in/dpSkaZdj #pharmaceuticals #manufacturing #biotechnology #biosimilars #translogconnect

🔬 Industry Insight: Radiopharmaceuticals Emerge as a Key Area for Investment and M&A At YOBE Ventures, we're always tracking the latest trends in investment opportunities. Recently, radiopharmaceuticals have caught our attention as a rapidly growing sector in the pharmaceutical industry. Key Developments: 1. Funding: Isotope Technologies Munich secured over $200 million in an equity round led by Temasek Holdings. 2. M&A Activity: AstraZeneca completed a $2.1 billion acquisition of Fusion Pharmaceuticals. 3. Startup Ecosystem: At least 12 private companies focused on radiopharmaceuticals have raised venture or growth funding in the past two years, totaling nearly $1.3 billion. 4. Clinical Promise: Treatments are showing potential for addressing some of humanity's most intractable diseases. This surge in investment aligns with our commitment to backing innovative companies that solve real-world problems. The radiopharmaceuticals sector combines cutting-edge science with significant market potential, making it an area ripe for smart investments. What are your thoughts on the future of radiopharmaceuticals? How do you see this impacting the broader healthcare and investment landscapes? #InvestmentTrends #Radiopharmaceuticals #VentureCapital #HealthcareInnovation #YOBEVentures

venBio Raises $528M for Fifth Life Sciences Fund - HIT Consultant #FundingNews: venBio raises $528M for fifth life sciences fund #VentureCapital #HealthcareInvestment VenBio, a leading life sciences investment firm, has successfully raised $528 million for its fifth fund, signaling strong investor confidence in the healthcare sector. #InvestmentStrategy: Focused on transformative healthcare technologies #LifeSciences #HealthcareInnovation VenBio's investment strategy revolves around identifying and supporting companies with innovative healthcare technologies that have the potential to transform patient care and outcomes. #PortfolioCompanies: Diverse range of healthcare startups #HealthTech #Biotech The firm's portfolio includes a diverse range of healthcare startups, spanning from digital health to biotech, reflecting VenBio's commitment to supporting innovation across ai.mediformatica.com #lifescience #investment #lifesciences #biopharmaceutical #investing #investments #medical #venturecapital #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4fzHbyx)